One of the on-going debates surrounds the question, should men with newly diagnosed advanced prostate cancer have a radical prostatectomy (RP). In a retrospective study, it was found that men lived longer if they had an RP followed by adjuvant radiotherapy (XRT). The study was reported in, Cancer, a very reputable Journal.
Circulating tumor cells (CTCs) are cancer cells that detach from a primary cancer tumor and enter a person’s bloodstream. Their goal is to move to another part of the body to form new metastases. These new metastatic lesions are more aggressive than the primary tumor and account for most of the cancer-related deaths.
Data from the phase 2/3 OSPREY 2301 Study has shown that the PSMA-targeted small molecule PET imaging agent (PyL (18F-DCFPyL) designed to better visualize prostate cancer outside of the gland demonstrated high sensitivity and reliably in detecting distant metastatic prostate cancer lesions and also a high specificity in confirming the absence of pelvic lymph nodes.
What is the proper target level for your testosterone to be considered castrate when you are on ADT?
Apalutamide (Erleada) extends time to the development of first metastatic development and it does not degrade the quality of life.
Our genes are continually mutating as our cells go through their normal process of replicating themselves. However, our bodies are blessed with other genes whose job it is to identify these mutations and then repair them before they do any damage, like give us cancer.
There are two phase 1 and 2 clinical trials reporting about a new PSMA targeting alpha emitting investigational radiation treatment. The trials are are very promising. They evaluate a new investigational treatment called Ac-225-PSMA-617.
We now need to wait for a phase 3 trial.
A typical reaction that we have to cancer is to become distressed. When feeling high levels or constant distress, you often feel as though you can’t handle the problems that you are facing. Stress is manifested in many different ways; mentally, physically, socially, or spiritually—or in any combination of these ways.
Jansen Pharmaceuticals has requested that we let our blog readers know about an upcoming educational webinar they are sponsoring on Tuesday, 9/18/18, 7 p.m. ET. The webinar will be discussing their newly approved treatment, apalutamide (Erleada) which is approved by the FDA for men with castrate resistant, non-metastatic prostate cancer, sometimes referred to as M0 (M-zero) disease.
Home healthcare can include many different services that are delivered to you in your home. Medicare will cover some of your home healthcare needs, however you will need to meet certain stringent conditions to be eligible for the coverage.
A study determined that there is a psychological morbidity rate of over 80% experienced by caregivers of patients with terminal cancer.
Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Through the work of Huggins et al.  in 1941, it was shown that metastatic prostate cancer responds positively to an orchiectomy (surgical castration). We now know that there isn’t any other therapy which produces a more reliable regression of both distant and local disease than androgen withdrawal (ADT).
Continuous long-term ADT significantly reduces the sensitivity and visibility of castration-sensitive prostate cancer on PSMA PET/CT scans.
In a recent study of 258 men with otherwise untreatable castrate resistant prostate cancer the immunotherapy drug Pembrolizumab showed that it was able to control the disease having a positive response lasting six months or more in 11 percent of men, with two men showing a complete response.
The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted. The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies.
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
The FDA now will accept Metastasis-Free Survival (MFS) as a clinical trial endpoint for hormone sensitive cancer.
Update 1- The Metastatic Prostate Cancer Project files its first report to its participants.
An estimated one-fifth or more men with metastatic castration-resistant prostate cancer (mCRPC) harbor defects in genes involved in their DNA repair pathway (e.g., BRCA2, BRCA1, and others).